Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT07352566
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • In situ cutaneous microdevice — DEVICE
    The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. The microdevice will contain a subset of the following: Triamcinolone, 5-fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast.
  • Triamcinolone — DRUG
    Triamcinolone
  • 5-Fluorouracil — DRUG
    5-fluorouracil
  • Calcipotriene — DRUG
    Calcipotriene
  • Tapinarof — DRUG
    Tapinarof
  • Crisaborole — DRUG
    Crisaborole
  • Tacrolimus — DRUG
    Tacrolimus
  • Adalimumab — DRUG
    Adalimumab
  • Etanercept — DRUG
    Etanercept
  • Certolizumab — DRUG
    Certolizumab
  • Infliximab — DRUG
    Infliximab
  • Secukinumab — DRUG
    Secukinumab
  • Ixekizumab — DRUG
    Ixekizumab
  • Apremilast — DRUG
    Apremilast
  • Risankizumab — DRUG
    Risankizumab
  • Ustekinumab — DRUG
    Ustekinumab
  • Hydroxychloroquine — DRUG
    Hydroxychloroquine
  • Methotrexate — DRUG
    Methotrexate
  • Mycophenolate — DRUG
    Mycophenolate
  • Azathioprine — DRUG
    Azathioprine
  • Chloroquine — DRUG
    Chloroquine
  • Cyclosporine — DRUG
    Cyclosporine
  • Tofacitinib — DRUG
    Tofacitinib
  • Deucravacitinib — DRUG
    Deucravacitinib
  • Dupilumab — DRUG
    Dupilumab
  • Tralokinumab — DRUG
    Tralokinumab
  • Guselkumab — DRUG
    Guselkumab
  • Tildrakizumab — DRUG
    Tildrakizumab
  • Baractinib — DRUG
    Baractinib
  • Abrocitinib — DRUG
    Abrocitinib
  • Upadacitinib — DRUG
    Upadacitinib
  • Lebrikizumab — DRUG
    Lebrikizumab
  • Nemolizumab — DRUG
    Nemolizumab
  • Ruxolitinib — DRUG
    Ruxolitinib
  • Bimekizumab — DRUG
    Bimekizumab
  • Roflumilast — DRUG
    Roflumilast

Study Details

This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis. The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.

Key Dates

Start date
Aug 1, 2026
Status verified
Jun 2026
Primary completion
Jun 1, 2030
Completion
Jun 1, 2030

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY

Arms

  • Experimental: In situ cutaneous microdevice
    The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.

Primary Outcome Measure

Number of participants with adverse events [ Time Frame: 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, San FranciscoSan FranciscoCalifornia94158-

Find similar trials in San Francisco, CA

By condition
Atopic dermatitis / eczemaPsoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
University of California, San Francisco· San Francisco, CA

Related Studies